Barbara H. Johnson, MBA

home / authors / barbara-h-johnson-mba

Articles

Compliance and Cost of Biologic Therapies for Rheumatoid Arthritis

Machaon Bonafede, PhD, MPH;Barbara H. Johnson, MBA;Derek H. Tang, PhD, BSPharm;David J. Harrison, PhD;Bradley S. Stolshek, PharmD

September 21st 2017

Medication compliance is associated with lower overall and disease-related healthcare costs in patients with moderate to severe rheumatoid arthritis receiving biologic therapies.

Pregabalin Prior Authorization and Potential Medication-Medication and Medication-Condition Interactions

Stephen S. Johnston, MA;Alesia Sadosky, PhD;Joseph C. Cappelleri, PhD;Barbara H. Johnson, MBA;George Shrady, MS;Bong-Chul Chu, PhD;Stuart Silverman, MD

March 2nd 2015

This study of patients treated with pregabalin or duloxetine found that pregabalin prior authorization policies were associated with increased exposure to potential medication-medication and medication-condition interactions.